Am J Transplant, Volume 16, Suppl 3 Archives - Page 84 of 180 - ATC Abstracts

2016 American Transplant Congress
NFκB Inhibitor Withaferin A Blocks IBMIR In Vitro: miRNA 375 Analysis.
M. Kanak,¹ M. Takita,² G. Yoshimatsu,² M. Lawrence,² M. Levy,¹ B. Naziruddin.³
¹Surgery, Virginia Commonwealth University, Richmond, VA; ²Islet Tranpsplant Lab, Baylor Research Institute, Dallas, TX; ³Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
Background: Instant Blood Mediated Inflammatory Reaction (IBMIR) has been shown to severely affect islet engraftment. We previously reported that Withaferin A (WA) can protect islets…
2016 American Transplant Congress
Dendritic Cells and Damage-Associated Molecular Patterns in Aging.
M. Seyda, H. Li, G. Liu, M. Quante, H. Uehara, J. Schuitenmaker, A. Elkhal, S. Tullius.
Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Boston.
Recently, it has been shown that Dendritic Cells (DCs) of old organs accelerate graft rejection by orchestrating IL-17A-mediated T cell responses. Moreover, cell-free DNA has…
2016 American Transplant Congress
Transplantation of Islet Preconditioned with Hydrogen Sulfide Enhances the Graft Function in Diabetic Mice.
D. Wang, M. Ding, J. Xue, J. Zheng, S. Feng, H. Tian, Y. Li.
Department of Renal Transplant, Center of Nephropathy, the First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, China.
Background: Islet transplantation is a promising therapy for Type 1 diabetes. However, successful outcomes are hampered by the poor survival of the donor cells after…
2016 American Transplant Congress
Nontuberculous Mycobacterial Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients: A 16-Year Cohort Study.
A. Alghamdi, J. Lipton, C. Rotstein, D. Kumar, A. Humar, T. Mazzulli, S. Husain.
University Health Network, Toronto, Canada.
Background: Nontuberculous mycobacteria (NTM) infections in hematopoietic stem cell transplant (HSCT) recipients can be associated with significant morbidity and mortality.Methods: We identified all allogeneic HSCT…
2016 American Transplant Congress
Epidemiology of Surgical Site Infections After Liver Transplantation: 4 Year Prospective Study.
Y. Natori, R. Kassar, A. Iaboni, S. Hosseini-Moghaddam, D. Vu, S. Husain, E. Renner, C. Rotstein.
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
IntroductionDeceased and living donor liver transplantation (LT) is a lifesaving procedure for individuals with liver failure. However, despite the use of perioperative antibiotic prophylaxis at…
2016 American Transplant Congress
Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Taclorimus with CsA for Two Years Result by a Japanese Multicenter Study.
N. Yoshimura, K. Nishimura, K. Akioka, M. Shimazu, K. Nose, T. Nishioka, N. Nakamura, K. Uchida, T. Nakatani, H. Ushigome.
Japanese Multicenter Study Group of High Dose Mizoribine in Kidney Transplantation, Kyoto, Japan.
(Aims) Mizoribine (MZR) has been developed as an immunosuppressive agent, but has a less potent immunosuppressive effect up to 3 mg/kg/day. The widespread use of…
2016 American Transplant Congress
Impact of Everolimus and Low-Dose Ciclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.
B. Höcker,¹ S. Zencke,¹ L. Pape,² K. Krupka,¹ L. Kösters,¹ A. Fichtner,¹ L. Dello Strologo,² I. Guzzo,² R. Topaloglu,² B. Kranz,² J. König,² M. Bald,² N. Webb,² A. Noyan,² H. Dursun,² S. Marks,² Z. Ozcakar,² F. Thiel,² H. Billing,² M. Pohl,² H. Fehrenbach,² P. Schnitzler,¹ T. Bruckner,¹ L. Weber,² R. Feneberg,² T. Ahlenstiehl-Grunow,² B. Tönshoff.¹
¹University Children's Hospital, Heidelberg, Germany; ²Certain Research Community, Germany, Italy, Turkey, United Kingdom.
Purpose: Preclinical studies indicate an anti-cytomegalovirus (CMV) activity of the mammalian target of rapamycin inhibitor (mTORi) everolimus (EVR), but data in pediatric renal transplant recipients…
2016 American Transplant Congress
Geographic Variability in Access to Transplant Centers for Children with End-Stage Renal Disease.
C. Toro,¹ M. Ross,^1,2 D. Wiebe,² S. Amaral.^1,2
¹Pediatrics, The Children's Hospital of Phila, Philadelphia, PA; ²Biostatistics and Epidemiology, The University of Pennsylvania, Philadelphia, PA.
Background: Kidney transplantation is the optimal treatment for pediatric end-stage renal disease (ESRD); yet, there is substantial variability in waiting times for deceased donor kidneys…
2016 American Transplant Congress
Compensating Live Kidney Donors: The Views of United States Voters.
J. Fisher,¹ T. Peters,² R. Gish,³ R. Howard.⁴
¹Surgery, Scripps Center for Organ Transplantation, La Jolla, CA; ²Surgery, University of Florida, Jacksonville, FL; ³Medicine, Stanford University Medical Center, Stanford, CA; ⁴Surgery, LifeQuest Organ Recovery Services, Gainesville, FL.
Purpose: An increasing number of U.S. patients die waiting for a kidney transplant. Financial compensation of living donors is one possible remedy for the organ…
2016 American Transplant Congress
The Heterogenous Genomic Landscape of Unresectable Hepatoblastoma Requiring Liver Transplantation: Prognostic Implications.
M. Ningappa, B. Higgs, S. Ranganathan, C. Ashokkumar, R. Sindhi.
Surgery, Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh, Pittsburgh, PA.
Background: Hepatoblastoma, the most common pediatric liver malignancy, is cured by chemotherapy and surgical resection. Locally invasive/multifocal tumors require liver transplantation (LTx). A unique tumor…